Editas Medicine pads runway with $50M upfront from Vertex for Cas9 license

As Editas Medicine attempts to catch up to the historic approval of Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited sickle cell treatment, the biotech will get $50 million in cash from the pack’s leader.

Vertex will dole out the upfront payment for a non-exclusive license…
Click here to view original post

Advertisement — Advertise with Biotech Networks